Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis
- 723 Downloads
Placebo and pharmacodynamic (PD) models were developed which link temporal measures of efficacy in children with attention deficit hyperactivity disorder (ADHD) and methylphenidate (MPH) plasma concentrations from adults. These models can be used to predict daily pediatric clinical measure profiles following administration of different MPH formulations in children without conducting pediatric pharmacokinetic (PK) or PD studies by using more easily obtained adult PK data. Mean PK data from various extended-release MPH formulations studied in adults and mean PD data from nine pediatric efficacy studies were obtained from the literature. The individual time-course of the clinical measures from three pediatric trials were also analyzed after being combined with the meta-analysis data. The clinical measure profiles following placebo administration were described by indirect response models with time-varying elimination rates. MPH pharmacodynamic effect was described by Emax models, which included time-dependent tolerance. Internal and external evaluations using a visual predictive check technique confirmed the prediction capability of the models. This modeling exercise demonstrated that time courses of MPH concentrations in adults with different drug release patterns can be used to predict time courses of clinical efficacy parameters in pediatrics by employing the models developed by meta-analysis.
KeywordsMethylphenidate pharmacodynamics Attention deficit hyperactivity disorder Meta-analysis Population modeling Placebo model
Conflict of interest disclosures
Ekaterina Gibiansky and Leonid Gibiansky are paid consultants of Johnson & Johnson. All the other authors are employees of Johnson & Johnson.
- 9.Swanson JM (2002) School-Based assessments and interventions for ADD students. KC Publishing, IrvineGoogle Scholar
- 11.Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ (2004) COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113(3 Pt 1):e206–e216PubMedCrossRefGoogle Scholar
- 12.Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R (2008) A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs 22(8):693–704PubMedCrossRefGoogle Scholar
- 13.Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R (2008) Efficacy and safety of extended-release dexmethylphenidate compared with d, l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 18(3):248–256PubMedCrossRefGoogle Scholar
- 15.Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A (2008) Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d, l-Methylphenidate and Placebo in a laboratory classroom setting. Psychopharmacol Bull 41(1):19–33PubMedGoogle Scholar
- 16.Silva RR, Muniz R, Pestreich L, Childress A, Brams M, Lopez FA, Wang J (2006) Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 16(3):239–251PubMedCrossRefGoogle Scholar
- 17.Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology April 13, 2010, BRIEFING INFORMATION p 32 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM207955.pdf (Accessed June 20, 2011)
- 22.Sonuga-Barke EJS, Swanson JM, Coghill D, DeCory HH, Hatch SJ (2004) Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28PubMedCrossRefGoogle Scholar